Extracts Trial Data - It pulls inclusion and exclusion criteria, trial details, and recruiting site locations from trusted sources like clinicaltrials.gov.

Analyzes Patient Information - The tool gathers both structured data, such as lab results and diagnosis codes, as well as unstructured data from free-text clinical documents within the patient’s medical record.

Matches Patients to Trials - Using this information, it assesses the patient’s potential eligibility for ongoing clinical trials recruiting in nearby locations, making it easier for providers to connect patients with relevant research opportunities.

Predicta Med is transforming the care of autoimmune diseases by offering an EMR-integrated platform that accelerates diagnosis and intervention. The platform includes three core modules:

• PredictaAI: The first AI-driven solution designed for early detection and tailored intervention of autoimmune diseases, enhancing diagnostic accuracy and speed.
• PredictaChart: The tool streamlines clinical decision-making, significantly reducing the time spent on patient chart reviews.
• PredictaMatch: A patient eligibility assessment tool, seamlessly embedded in EMRs, providing healthcare providers with relevant treatment options based on a patient’s disease profile.

Together, these modules enable faster, more accurate care decisions, improving outcomes for patients with autoimmune diseases

23andMe has more than 12 million customers worldwide. Our Health + Ancestry Service allows individuals to acquire this information from the privacy of their own homes, without medical requisition. Nearly 30% of consumers who undergo direct-to-consumer (DTC) genetic testing choose to share their reports with healthcare providers to inform conversations about their health.1,2,3 Our Healthcare Professionals community was created to help U.S. providers and their patients navigate genetics together in order to make important informed decisions about prevention, treatment and healthy living.

23andMe is a human genome research company enabling users to study their ancestry, genealogy, and inherited traits. A startup co-founded by Linda Avey and Anne Wojcicki, the wife of Google co-founder Sergey Brin, 23andMe has plans to make the human genome searchable. Brin, along with Google, gave 23andMe $3.9 million as part of a series A in May of 2007. The company was named after the number of chromosome pairs in humans. They aim to help people understand what their genes mean by indexing them and highlighting significant findings. 23andMe allows its clients/users to study their ancestry, genealogy, and inherited traits. The company also markets to researchers and scientists, for whom they provide neatly categorized and easily searchable data. One reason the Google investment in 23andMe made sense, was that this company could enable the search giant to index another facet of the world's information. With the Biotech and Health Care industries growing rapidly, 23andMe could help Google get and maintain a market hold in these already multi-billion dollar areas.

AI-Driven Patient Matching: Identify high-potential cohorts earlier in their disease progression.

Heatmap Analytics: Pinpoint where your target populations are most concentrated.

AI-Driven Patient Matching: Identify high-potential cohorts earlier in their disease progression.

Heatmap Analytics: Pinpoint where your target populations are most concentrated.